Caredx Stock Price, News & Analysis

CareDx (Nasdaq: CDNA) will participate in the National Kidney Foundation's 2021 Spring Clinical Meetings from April 6-10, 2021. The company will host a virtual exhibitor showcase titled “Next Generation Care for Kidney Transplant Patients” on April 6, featuring experts like Dr. Christopher Boshkos and Dr. Matthew Weir discussing AlloSure, a standard for kidney transplant surveillance. Additionally, CareDx will sponsor a CME program on April 8 focusing on acute rejection in kidney transplantation, showcasing leading medical professionals' insights.

CareDx, a precision medicine company, has recently announced key leadership appointments to bolster its growth and enhance the patient experience in transplant healthcare. Reg Seeto, President and CEO, emphasized a commitment to innovation and patient-focused integrated digital offerings. New hires include Titte R. Srinivas, M.D., as VP of Digital Development, and Steven Stone, Ph.D., as VP of KidneyCare. Promotions include Marica Grskovic, Ph.D., to VP of Cell Transplant Therapy, reflecting the company’s dedication to improving transplant patient care.

CareDx, Inc. (Nasdaq: CDNA) announced efforts to raise awareness for Vir Biotechnology’s COMET-ICE study, evaluating the monoclonal antibody VIR-7831 for early COVID-19 treatment in high-risk adults. The trial, which focuses on the immune-compromised transplant patient population, was halted for enrollment following recommendations from an Independent Data Monitoring Committee due to significant efficacy. CareDx aims to facilitate patient access to clinical trials, providing additional treatment options beyond vaccines for vulnerable transplant patients.

CareDx, a precision medicine company focused on transplant solutions, has acquired BFS Molecular, a software firm specializing in NGS-based patient testing. This acquisition strengthens CareDx's portfolio with advanced software and algorithm development capabilities for transplant surveillance products like AlloSeq cfDNA and AlloSeq HCT. Tim Hague, the former CEO of BFS Molecular, will join CareDx as Vice President of Global Lab Products Software, enhancing their bioinformatics expertise and presence in Europe. CareDx aims to improve the transplant patient journey through this strategic acquisition.

CareDx, Inc. (Nasdaq: CDNA) announced the appointment of Ankur Dhingra as the new Chief Financial Officer, effective March 25, 2021. Dhingra brings over 25 years of finance and accounting experience, previously serving as Vice President of Investor Relations at Agilent Technologies. CEO Reg Seeto expressed confidence that Dhingra's expertise will enhance operational growth and financial performance at CareDx. The company focuses on precision medicine for transplant patients, offering various healthcare solutions throughout the entire transplant journey.

CareDx, Inc. (Nasdaq: CDNA) announced the acquisition of TX Services, LLC, including its TX Connect service, which adds 19,000 patient referrals for kidney transplants. This cloud-based service allows nephrologists and dialysis centers to streamline electronic referrals to transplant programs. The integration enhances CareDx's pre-transplant offerings, complementing existing services like XynManagement. CEO Reg Seeto highlighted that TX Connect aids in helping more kidney patients get on transplant waitlists, enhancing patient care through better communication and management across the healthcare continuum.

CareDx, a precision medicine company, reported strong financial results for Q4 and full-year 2020. Q4 revenue reached $58.6 million, a 64% increase year-over-year, contributing to a record $192.2 million for the full year, up 51% from 2019. The company achieved a non-GAAP net income of $4.3 million in Q4 and $11.3 million for the full year. Despite a GAAP net loss of $3.5 million in Q4, the results signal a positive trajectory. Additionally, CareDx has provided over 79,000 patient results in 2020 and received Medicare reimbursement for AlloSure Heart.

CareDx, Inc. (Nasdaq: CDNA) is set to showcase its AlloSure donor-derived cell-free DNA (dd-cfDNA) technology at the Cutting Edge of Transplantation Meeting, occurring from February 25-27, 2021. Key presentations will include the ADMIRAL study, highlighting AlloSure's effectiveness in detecting allograft rejection among over 1,000 patients across various transplant centers. Additional research will be presented on the clinical applications of dd-cfDNA in real-life settings, including case studies and its relevance during the COVID-19 pandemic. CEO Reg Seeto emphasized the significance of these findings for post-transplant patient care.

CareDx, Inc. (CDNA) will release its financial results for the fourth quarter and full year 2020 after market close on February 24, 2021. A conference call is scheduled for 1:30 p.m. PT / 4:30 p.m. ET, with dial-in numbers available for domestic and international callers. CareDx is renowned for its precision medicine solutions for transplant patients, offering testing services and digital healthcare solutions.